What did @bloombergbusiness actually say?
The Bloomberg Business interview featured Novo Nordisk CEO Maziar Mike Doustdar arguing that compounded semaglutide represents a patient safety crisis and an intellectual property violation. He said the FDA and DOJ acted "swiftly" against Hims and Hers, and that compounding should be "reserved for a few individuals" with allergies, not mass-marketed. He specifically flagged "API coming from unknown sources, often China" as dangerous.
This is a CEO protecting his company's revenue. That context matters. But the claims he makes about regulatory violations and API sourcing are grounded in real documented concerns, even if his framing is self-serving. Doustdar is not a neutral observer here. Novo Nordisk has a direct financial interest in shutting down the compounding market, which was estimated to be worth billions in diverted Wegovy and Ozempic sales during the shortage period.
Does the science back this up?
On API safety, the concern is legitimate, though frequently overstated. The FDA has flagged compounded semaglutide made with semaglutide sodium and acetate salts as not equivalent to the approved drug, and issued warnings accordingly. Whether that translates to real patient harm at scale is less clear-cut than Doustdar implies.
The FDA's own shortage list rules allowed compounders to legally produce semaglutide during verified shortages. When the FDA declared the shortage resolved in early 2025 for Wegovy, the legal basis for large-scale compounding evaporated. Several 503B outsourcing facilities contested this, arguing the shortage was not genuinely resolved for all doses. Doustdar frames this as a clean legal victory, but litigation is ongoing. On the API source question, studies on counterfeit and unregulated peptides do show contamination risks. A 2023 FDA import alert listed multiple Chinese API suppliers for semaglutide as adulterated or misbranded. That is real. But blanket claims that all compounded product is dangerous sidestep the fact that FDA-registered 503A and 503B compounders operate under inspection and quality standards.
What did they get wrong (or right)?
Doustdar got the broad regulatory direction right. The FDA did move against mass-market compounders, and the legal environment has tightened considerably in 2025. His framing of the Super Bowl commercials as evidence of illegal mass compounding is actually a sharp observation. When a compounding pharmacy runs national advertising, it has arguably abandoned the individualized patient relationship that defines legal compounding under the FDCA.
Where he oversimplifies: compounding is not just for people with allergic reactions. The FDCA allows compounding for patients with documented clinical needs that branded products cannot meet, including dosage adjustments, excipient sensitivities, and access barriers. Framing it as only for allergies is legally and clinically inaccurate. He also conflates all compounded semaglutide with unsafe API. Some compounders used verified, FDA-compliant API. The FDA's enforcement actions targeted specific bad actors, not every compounder. That distinction matters for patients who accessed compounded product from legitimate pharmacies and are worried about what they took.
What should you actually know?
If you used compounded semaglutide during the shortage period, the most important question is whether your pharmacy was a registered 503A or 503B facility using USP-grade API from a verified domestic or inspected foreign source. That is not a minor administrative detail. The FDA warning letters issued in 2024 and 2025 specifically called out semaglutide sodium and acetate salts as unapproved forms of the drug, meaning some products labeled as semaglutide may not have contained the same active molecule as Ozempic or Wegovy.
Doustdar's IP argument is legally sound but emotionally convenient. Yes, pharmaceutical innovation requires patent protection. It is also true that Novo Nordisk has faced criticism for US pricing that made branded semaglutide inaccessible to many patients without insurance coverage, which is part of why the compounding market grew so fast. Both things are true at once. The FDA's resolution of the shortage declaration was contested by compounders and some patient advocates who argued supply remained uneven. Federal courts have been hearing those challenges. This is not fully settled law.